Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Molecular Profile Unknown unknown
Therapy E7046
Indication/Tumor Type Advanced Solid Tumor
Response Type not applicable


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable E7046 Phase I Actionable In a Phase I trial, E7046 treatment resulted in no objective responses, only stable disease in 13% (4/30) and metabolic responses in 13% (4/30) of patients with advanced solid tumors (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 373PD; NCT02540291). detail...
Unknown unknown Advanced Solid Tumor not applicable E7046 Preclinical Actionable In a preclinical study, multiple mouse tumor models demonstrated inhibition of tumor growth when treated with E7046 (Cancer Immunol Res 2016;4(1 Suppl):Abstract nr B034). detail...
PubMed Id Reference Title Details
Abstract B034: Preclinical immune antitumor activity of myeloid-targeting E7046 and Treg depleting E7777 Full reference...
Phase 1 Study of E7046, a PGE2 Receptor EP-4 inhibitor that targets immunosuppressive myeloid cells in the tumor microenvironment Full reference...